Price$4.80+1.74 (+56.86%)
2026-04-142026-07-17
News · 26 weeks47+120%
2026-01-182026-07-12
Mix1890d
- Insider10(56%)
- Other4(22%)
- SEC Filings4(22%)
Latest news
25 items- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeTEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that its subsidiary NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany ("MHH"), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing
- INSIDERAmendment: New insider Adler Oz claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Revach Moshe claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Shay Amnon Ben claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Sidi Liat claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Dayan Alon claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Weiss Amitay claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Vider Lior claimed ownership of 3,649 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Shrem Itschak claimed ownership of 11,058 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERAmendment: New insider Zuloff-Shani Adi claimed ownership of 5,528 units of Ordinary Shares (SEC Form 3)3/A - SciSparc Ltd. (0001611746) (Issuer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantumTEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum"). According to the share purchase agreement (the "SPA"), pursuant to which, NeuroThera acquired 56,375 ordinary shares of CliniQuatum (the "Transaction"), representing approximately 54% of the issued and outstanding ordinary shares of CliniQuantum, in consideration for the issuance of 56,600,0
- INSIDERDirector Shrem Itschak sold $4,620 worth of Ordinary Shares (462 units at $10.00), decreasing direct ownership by 4% to 10,596 units (SEC Form 4)4 - SciSparc Ltd. (0001611746) (Issuer)
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- PRSciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantumTEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange ("TSX") for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction"). As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the "Selling Shareholders") entered into a share purchase agreement (the "SPA"), pursuant to which, N
- SECSEC Form 6-K filed by SciSparc Ltd.6-K - SciSparc Ltd. (0001611746) (Filer)
- SECSEC Form 20-F filed by SciSparc Ltd.20-F - SciSparc Ltd. (0001611746) (Filer)
- INSIDERSEC Form 3 filed by new insider Dayan Alon3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zuloff-Shani Adi3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Vider Lior3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Adler Oz3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shrem Itschak3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sidi Liat3 - SciSparc Ltd. (0001611746) (Issuer)
- INSIDERSEC Form 3 filed by new insider Revach Moshe3 - SciSparc Ltd. (0001611746) (Issuer)
SPRC FAQ
5 questionsWhat does SciSparc Ltd. do?
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health...Where does SPRC stock trade?
SciSparc Ltd. (SPRC) is listed on NASDAQ.What sector and industry is SPRC in?
SciSparc Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SPRC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SPRC side-by-side with any of them on Quantisnow.How can I track SPRC on Quantisnow?
Quantisnow aggregates SciSparc Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRC to receive live email and push alerts on every new disclosure.